Pharmaceuticals, Biotechnology and Life Sciences
Net Product Revenue for Auryxia Increases to $23.1 Million for Q1’FY19, Up 12.1% from Q1’FY18; Full Enrollment of Phase 3…
DUBLIN–(BUSINESS WIRE)–The “Global Laryngeal Cancer Therapeutics Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering. The laryngeal cancer therapeutics market…
— Six-month follow-up on patients with cerebral adrenoleukodystrophy (cALD) shows stable neurological function scores and early and persistent resolution of…
Alpine transitions to clinical-stage company Completed financing to fund further development of both lead programs SEATTLE–(BUSINESS WIRE)–Alpine Immune Sciences, Inc.…
An additional treatment modality would provide more flexibility in how patients receive vedolizumab, a biologic with a gut-selective mode of…
Phase 2 gMG long-term extension data show durability of zilucoplan treatment effect, with sustained improvements in primary and secondary endpoints…
YCGP’s “With Love, Me” Letters Campaign Brings Together Cancer Survivors and Caregivers to Share Their Heartfelt Personal Stories with Others…
–Conference Call and Webcast Today at 8:00 a.m. ET– WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused…
On Track to Initiate Phase 1b Clinical Trial of Topical Drop Formulation of AKB-9778 for Primary Open-Angle Glaucoma (POAG) in…
Increasing visibility of potential study participants to sites and sponsors DUBLIN–(BUSINESS WIRE)–ICON plc, (NASDAQ: ICLR) a global provider of drug…